Live feed07:30:00·6mPRReleasevia QuantisnowImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid TumorsByQuantisnow·Wall Street's wire, on your screen.IMNM· Immunome Inc.Health Care
